SNY vs. TAK: Sanofi vs. Takeda Pharmaceutical Stock Comparison

November 11, 2026

How do Sanofi (SNY) and Takeda Pharmaceutical (TAK) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Sanofi (SNY) and Takeda Pharmaceutical (TAK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Both Sanofi (SNY) and Takeda Pharmaceutical (TAK) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Company profile comparison for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Profile Item	SNY	TAK
Name	Sanofi ADR	Takeda Pharmaceutical Co Ltd ADR
Country/Region	France	Japan
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	112.71 billion USD	67.16 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	July 1, 2002	January 5, 2010
Security Type	ADR	ADR

Price Performance

Cumulative Growth

SNY

TAK

GSPC

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Sanofi (SNY) and Takeda Pharmaceutical (TAK). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Sanofi (SNY) and Takeda Pharmaceutical (TAK). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Total Return (1Y)	2.73%	54.54%
Total Return (3Y, Annualized)	6.89%	18.39%
Total Return (5Y, Annualized)	3.16%	9.29%

Risk Profile

Drawdown History

SNY

TAK

GSPC

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Sanofi (SNY) and Takeda Pharmaceutical (TAK). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Sanofi (SNY) has a non-negative beta of 0.28.

Risk profile metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Volatility (1Y, Annualized)	23.60%	21.45%
Beta (5Y)	0.28	-0.01
Max Drawdown (5Y)	-33.52%	-24.83%
Avg. Volume (3M)	3.29M	2.61M

Risk-Adjusted Performance

Risk-Return Positioning

SNY and TAK are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Sharpe Ratio (1Y)	-0.07	2.34
Sortino Ratio (1Y)	-0.10	3.88

Profitability

ROE (TTM)

Both Sanofi (SNY) at 5.72% and Takeda Pharmaceutical (TAK) at 0.56% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max: 109.18%
Q3: 6.23%
SNY: 5.72%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56%

Max: 109.18%
Q3: 6.23%
TAK: 0.56%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Sanofi (SNY) at 8.20% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max: 18.05%
SNY: 8.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87%

Max: 18.05%
Q3: 4.78%
TAK: 0.87%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Sanofi (SNY) at 30.89% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max: 83.12%
SNY: 30.89%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.55%

Max: 83.12%
TAK: 24.55%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
ROE (TTM)	5.72%	0.56%
ROA (TTM)	5.31%	3.27%
Net Margin (TTM)	8.20%	0.87%
Operating Margin (TTM)	30.89%	24.55%
Gross Margin (TTM)	73.68%	64.77%

Growth

Revenue Growth

Sanofi (SNY) at 5.49% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their Revenue Growth across different time periods.

EPS Growth

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Sanofi (SNY) at 39.43% is closer to the peer norm — faster per-share earnings growth for TAK.

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Revenue Growth (YoY)	5.49%	-1.66%
Revenue Growth (3Y CAGR)	4.82%	3.81%
EPS Growth (YoY)	39.43%	77.96%
EPS Growth (3Y CAGR)	6.02%	-16.01%

Financial Strength

Current Ratio (MRQ)

Both Sanofi (SNY) at 1.12 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
SNY: 1.12
Min: 0.10

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.15

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TAK: 1.15
Min: 0.10

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max: 1.42
Q3: 0.65
SNY: 0.27
Median: 0.15
Q1: 0.02
Min: 0.00

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.72

Max: 1.42
TAK: 0.72
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Current Ratio (MRQ)	1.12	1.15
Debt / Equity (MRQ)	0.27	0.72
Net Debt / EBITDA	0.96	3.61

Dividends

Dividend Yield (TTM)

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

953.28%

TAK: 953.28%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Sanofi (SNY) at 119.86% and Takeda Pharmaceutical (TAK) at 426.53% report payout ratio above 100%, meaning dividends exceeded current-period earnings on both sides.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY: 119.86%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

426.53%

TAK: 426.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
Dividend Yield (TTM)	0.00%	953.28%
Dividend Payout Ratio (TTM)	119.86%	426.53%

Valuation

P/E Ratio (TTM)

Sanofi (SNY) at 23.40 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max: 85.34
Q3: 43.46
Median: 26.69
SNY: 23.40
Q1: 13.30
Min: 0.07

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

300.29

TAK: 300.29
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Both Sanofi (SNY) at 2.21 and Takeda Pharmaceutical (TAK) at 0.01 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
SNY: 2.21
Min: 0.01

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
TAK: 0.01
Min: 0.01

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Relative to net asset value, both Sanofi (SNY) at 1.38 and Takeda Pharmaceutical (TAK) at 1.43 look inexpensive, sitting in the lower P/B ratio quartile of their industries.

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
SNY: 1.38
Min: -5.59

TAK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.43

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
TAK: 1.43
Min: -5.59

Sanofi (SNY) vs. Takeda Pharmaceutical (TAK): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Sanofi (SNY) and Takeda Pharmaceutical (TAK)
Metric	SNY	TAK
P/E Ratio (TTM)	23.40	300.29
P/S Ratio (TTM)	2.21	0.01
P/B Ratio (MRQ)	1.38	1.43
Free Cash Flow Yield (TTM)	7.17%	1,014.61%